2′-Deoxy-2′,2′-difluoroguanosine is a modified nucleoside that belongs to the class of antiviral and anticancer agents. Its structure features a guanine base attached to a deoxyribose sugar, with two fluorine atoms substituted at the 2′ position of the sugar moiety. This modification enhances its stability and bioavailability compared to natural nucleosides. The presence of fluorine atoms can also influence the compound's interaction with nucleic acid targets, potentially altering its pharmacological properties. 2′-Deoxy-2′,2′-difluoroguanosine has been studied for its ability to inhibit viral replication and its potential use in cancer therapy, as it may interfere with nucleic acid synthesis in rapidly dividing cells. Additionally, its unique chemical properties allow for incorporation into RNA and DNA, which can be leveraged in therapeutic applications. As with many nucleoside analogs, the efficacy and safety profile of this compound are subjects of ongoing research, particularly in the context of its use in clinical settings.

2′-Deoxy-2′,2′-difluoroguanosine

103882-87-7: 2',2'-Difluorodeoxyguanosine, 2'-Deoxy-2',2'-difluoroguanosine, 2′,2′-Difluorodeoxyguanosine, 2′-Deoxy-2′,2′-difluoroguanosine, Guanosine, 2′-deoxy-2′,2′-difluoro-, Ly 223592

2'-Deoxy-2',2'-difluoroguanosine

2'-Deoxy-2',2'-difluoroguanosine (DFG) is an analog of guanosine that has been used to study the effect of guanylate kinase on cellular proliferation. This compound has also been shown to have a cytotoxic effect on leukemia cells. DFG has been shown to inhibit the growth of cancer cells and induce apoptosis in HL-60 leukemia cells. It has also been shown to inhibit the synthesis of DNA, RNA, and proteins. These effects are due to inhibition of guanylate kinase activity and may be related to its ability to cause the release of intracellular calcium ions.

CAS 103882-87-7: 2′-Deoxy-2′,2′-difluoroguanosine

2'-Deoxy-2',2'-difluoroguanosine

Ref: IN-DA00925P

2'-Deoxy-2',2'-difluoroguanosine

Ref: 3D-ND158376